Role of Biomarkers in Cancer Diagnosis and Therapeutics

Nyhet

Häftad, Engelska, 2026

AvSushama Talegaonkar,Lalit Kumar,Dalapathi Gugulothu

2 589 kr

Beställningsvara. Skickas inom 7-10 vardagar. Fri frakt för medlemmar vid köp för minst 249 kr.

Role of Biomarkers in Cancer Diagnosis and Therapeutics offers a thorough exploration of the critical roles biomarkers play in cancer detection, diagnosis, monitoring, and therapy. Sections focus on established and emerging biomarkers like PSA and CEA, detailing their biochemical characteristics and clinical relevance, and examining metabolic pathways utilized by cancer cells, highlighting key enzymes and their therapeutic potential. The final part pf the book discusses innovative strategies targeting cell cycle checkpoints and DNA repair mechanisms, including synthetic lethality through PARP inhibitors. This essential resource provides researchers and clinicians with insights into novel metabolic targets and cutting-edge treatment strategies.

By addressing current applications and future challenges, including the integration of AI and multi-omics approaches, the book equips readers with actionable knowledge to advance personalized cancer care and navigate the dynamic landscape of oncology.

Provides an in-depth analysis of both established and emerging cancer biomarkers, detailing their biochemical characteristics, clinical relevance, and diagnostic potential across various malignancies
Explores critical metabolic pathways utilized by cancer cells, highlighting key enzymes and their therapeutic implications, thereby offering insights into novel targets for cancer treatment
Discusses cutting-edge approaches that target cell cycle checkpoints and DNA repair mechanisms, including the concept of synthetic lethality, thus equipping readers with advanced knowledge for personalized cancer therapies

Produktinformation

Utgivningsdatum2026-03-27
Mått191 x 235 x 34 mm
Vikt450 g
FormatHäftad
SpråkEngelska
Antal sidor684
FörlagElsevier Science
ISBN9780443440410

Tillhör följande kategorier

Dr. Sushama Talegaonkar is an Associate Professor at the Department of Pharmaceutics, Delhi Pharmaceutical Sciences and Research University, India. She has approximately 21 years of experience, and has published more than 220 research papers in high impact international journals. Besides this, she has coauthored 6 books and authored 15 chapters in international reference books. Recently, she received the Professor C. J. Shishoo Award for Best Research. Her research paper titled “Development and bioavailability assessment of ramipril nanoemulsion formulation has received the most cited research paper award on behalf of Elsevier and the board of European Journal of Pharmaceutics and Biopharmaceutics. She was awarded the prestigious Motan Devi Dandiya Biennial Prize for best publication in Pharmaceutical Sciences for the period 2010–11. Dr. Talegaonkar is actively involved in developing a wide variety of smart and functionalized nanodrug delivery systems for targeted anticancer drug delivery. Lalit Kumar is an Assistant Professor in the Department of Pharmaceutics at the National Institute of Pharmaceutical Education and Research, Hajipur, Vaishali, Bihar, India. His area of research includes the development of nanocarriers for drug-targeting tumor cells in the colon, brain, breast, and lungs. Dr. Dalapathi Gugulothu working as Assistant professor, Department of Pharmaceutics , Delhi Institute of Pharmaceutical Sciences and Research, Delhi Pharmaceutical Sciences and Research University , New Delhi.

I. Biomarkers in Cancer Diagnosis and Treatment1. Prostate-Specific Antigen (PSA)2. Carcinoembryonic Antigen (CEA)3. Tissue Polypeptide-Specific Antigen (TPS) CA72-44. Carbohydrate Antigen 19-9 (CA19-9)5. Carbohydrate Antigen 125 (CA-125)6. Carbohydrate Antigen 72-4 (CA72-4)7. Aminopeptidase N8. Alkaline Phosphatase9. CD26/Dipeptidyl Peptidase (DPP)410. Genetic Biomarkers in Cancer11. Immunology Biomarkers in Cancer12. Microbiome Biomarkers in Cancer13. Glycobiology Biomarkers in Cancer14. Epigenetic Biomarkers in CancerII. Metabolic Targets and Cancer Therapeutics15. Introduction to Metabolic Targets and Autophagy16. Glucose Metabolism – Hexokinase-2 (HK2), Lactate Dehydrogenase A (LDHA), Pyruvate Kinase M2 Isoform (PKM2), Pyruvate Dehydrogenase (PDK), Glucose Transporter, Enolase 1 (ENO1), and Monocarboxylate Transporter (MCT1)17. Nucleic Acid Metabolism – Folate Cycle, Nucleotide Incorporation (DNA Polymerase/Ribonucleotide Reductase (RNR)), Deoxynucleotide Synthesis (RNR), and Thymidine Synthesis (TYMS)18. Amino Acid Metabolism – Arginine and Asparagine, Serine/Threonine Protein Kinase (Glycogen Synthase Kinase-3 (GSK-3))19. Glucose and Amino Acid Metabolism - Isocitrate Dehydrogenase-1 (IDH-1)20. Glucose, Nucleic Acid, Fatty Acid, and Amino Acid Metabolism – Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH)III. Miscellaneous Cancer Therapeutic Approaches21. Targeting DNA Repair Pathways – O-6-Methylguanine-DNA Methyltransferase (MGMT), Base Excision Repair, Double Strand Breaks Repair, and mtDNA Repair22. Cell Cycle Inhibition – Cyclin-Dependent Kinases (CDKs), and G1 Checkpoint23. Topoisomerase-Induced DNA Damage and Therapeutic Potential24. Polo-like Kinase 4 (PLK4) Inhibitors in Cancer Therapy25. Synthetic Lethality by Poly (ADP-Ribose) Polymerase Inhibitors26. Innovative Therapeutic Approaches